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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of education programmes for skin cancer prevention in the general population.
B A C K G R O U N D
Description of the condition
Skin cancer is a term that includes both melanoma and ker-
atinocyte cancer. Keratinocyte cancer (also known as non-
melanoma skin cancer) generally refers to basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC), although it also in-
cludes other rare cutaneous neoplasms (Madan 2010). Skin can-
cer is the most common cancer in populations of predominantly
fair-skinned people (Donaldson 2011; Lomas 2012; Stern 2010),
with incidence increasing (Garbe 2009; Leiter 2012). There are
variations in annual incidence rates between these populations,
with Australia reporting the highest rate of skin cancer in the
world (Lomas 2012). In 2012, the estimated age-standardised in-
cidence rate for melanoma was almost 63 per 100,000 people
for Australian men, and 40 per 100,000 people for Australian
women (AIHW 2012). In Europe, incidence rates range from 10
to 15 per 100,000 people (Garbe 2009; Lasithiotakis 2006), with
rates highest amongst men (Stang 2006). In the United States,
incidence rates are approximately 18 per 100,000 people (Garbe
2009), with the highest rates reported for women (Bradford 2010).
Keratinocyte cancer is much more common than melanoma. In
2012, the estimatedAustralian age-standardised rates for BCC and
SCC were 884 and 387 per 100,000 people, respectively (Staples
2006). The cumulative three-year risk of developing a subsequent
keratinocyte cancer is 18% for SCC and 44% for BCC (Marcil
2000).
Melanoma is the most fatal form of skin cancer. In 2007, the
melanoma mortality rate was 8.9 and 3.5 per 100,000 people for
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Australian men and women, respectively (AIHW 2012). In 2003,
Finland reportedmortality rates of 0.8 per 100,000people for both
men and women (Stang 2006). Amongst non-Hispanic whites in
the United States, mortality was 1.7 per 100,000 people for those
agedunder 65 years (Linos 2009).Generally,mortality rates of skin
cancer have been stabilising or declining (Cohn-Cedermark 2000;
Giles 1996; Jemal 2008), although this trend appears to be hap-
pening for women but not for men (Giles 1996; Jemal 2008; Stang
2006; Thompson 2005) or older people (Linos 2009). Survival
rates from melanoma have been improving (Thompson 2005),
with five-year survival in the United States and 10-year survival
in Germany both approximately 80% (Leiter 2012; Singh 2003),
and over 90% for young American adults (Reed 2012). High sur-
vival rates and improvements in melanoma mortality rates are
likely to be due to improvements in early detection and treatment
(Chapman 2011; Garbe 2009; Giles 1996). Keratinocyte cancer,
by contrast with melanoma, is less fatal yet can cause disfigure-
ment, often on visible areas of the body (English 1997). It is the
most common cause of hospitalisations for cancer, accounting for
11% of all inpatient cancer hospitalisations in Australia (AIHW
2012). For individuals, keratinocyte cancer can cause impairment,
financial strain, and distress (Burdon-Jones 2010; Leiter 2008).
For the healthcare system, skin cancer is one of the most costly
cancer groups (Housman 2003), with keratinocyte cancer the driv-
ing force behind high costs. While melanoma cost the Australian
health system 30 million Australian$ between 2000 and 2001,
keratinocyte cancer cost 264 million Australian$ (AIHW 2005).
In the United States, keratinocyte cancer is estimated to cost over
450 million US$ per year (Chen 2001).
Risk factors for skin cancer include genotype (an individual’s ge-
netic makeup); phenotype (the body’s expression of that geno-
type), both of which determine an individual’s predisposition to
skin cancer; and environmental factors. The primary environ-
mental risk factor is exposure to ultraviolet (UV) radiation from
the sun (IARC 1992; Kricker 2007; Madan 2010; Ramos 2004).
Melanoma and BCC appear to be associated with intermittent
and childhood sun exposure, whereas SCC appears to be related to
constant, cumulative sun exposure (Gallagher 2010).While geno-
type, phenotype, and ambient UV exposure cannot be altered, in-
dividuals have considerable control over their sun protection be-
haviours.
Cancer authorities recommend five adjunctive methods of sun
protection, in addition to avoidingpeakUV sunwherever possible:
1. seek shade;
2. wear sun-protective clothing;
3. wear sun-safe hats;
4. apply broad-spectrum, water-resistant, SPF 30+ sunscreen
to sun-exposed skin; and
5. wear sun-protective sunglasses (Cancer Council Australia
2013).
These methods have been shown to be effective. In the case of
sunscreen, correct usage during childhood is thought to reduce
lifetime skin cancer risk by 78% (Stern 1986); daily usage can
prevent development of melanoma and SCC; and in the long-
term, it may also protect against BCC (Green 1999; Green 2011;
Van der Pols 2006). Recent in vivo studies have shown that correct
application of SPF 30+ sunscreen can prevent all three cancer
types (Hacker 2013). However, each of the adjunctive methods of
sun protection encompass several elements, which can make the
behaviour, and measuring the behaviour, complex.
Despite these challenges, evidence suggests that interventions
aimed at improving people’s sun protection behaviours can work.
The sustainability of such programmes, however, is less clear. In
Australia, despite years of sun protection programmes, improve-
ments in these behaviours appear to have stabilised or worsened
(Green 2013; Livingston 2007; Markin 2013). This decrease may
be due in part to concerns about potential negative consequences
from low serum 25(OH)-vitamin D concentrations. Ultraviolet
radiation exposure is required for vitamin D synthesis, and low
serum concentrations, which have been associated with growth re-
tardation and skeletal deformation in children, and osteoporosis,
cancers, autoimmune diseases, infectious diseases, and cardiovas-
cular disease in adults (Holick 2007), may result from sun pro-
tection behaviours (Matsuoka 1987). Unclear or unbalanced mes-
sages regarding the vitamin D benefits and the skin cancer risks
of sun exposure may also lead to confusion regarding the required
level of sun protection (Hiom 2006; Langbecker 2011).
Description of the intervention
As described byWelsh 2011, education involves more than simply
providing information, aiming to integrate knowledge, improve
self-management, and produce behaviour change. Health educa-
tion can include ’training’, and consequently it is necessary to dis-
tinguish between education, which focuses on imparting knowl-
edge and developing understanding, and training, which focuses
on the development of skills (Michie 2011).
Interventions to reduce UV exposure are diverse and difficult to
classify (Saraiya 2004). Interventions may use various media (e.g.
posters, television and radio, and internet) and target multiple
audiences (e.g. parents, children, high-risk groups, and healthcare
providers) usingmultiple strategies (e.g. individuals, communities,
and populations) in multiple contexts and settings (e.g. schools,
healthcare settings, and recreational areas).
For the purposes of this review, we defined education as an inter-
vention to provide information on (a) skin cancer, (b) its causes,
(c) its consequences, or (d) how it can be prevented. Based on the
definition by Wolf 2002, such interventions may use any instruc-
tional strategy or combination of strategies (e.g. problem solving,
role-playing, videotapes, computer-assisted instruction, or book-
lets). These interventions may be delivered to the individual, via
group sessions or through general media, including online and so-
cial media. Interventions can be targeted at the general population
or specific high-risk groups (e.g. outdoor workers).
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Education interventions can address different levels of prevention,
although this review will only consider primary prevention pro-
grammes.
Primary prevention
The aim of the intervention is to reduce the risk of skin cancer by
informing people how to minimise UV radiation exposure.
Secondary prevention, which is not the subject of this review, is an
intervention that aims to increase appropriate healthcare service
use in response to signs of skin cancer (e.g. recognise skin changes
and seek early diagnosis and treatment) and reduce the risk of
reoccurrence or further development of skin cancer (Spratt 1981).
How the intervention might work
Educational interventions aim to change sun-protective behaviour
by informing people of the severity and consequences of skin can-
cer (e.g. death), the risk factors associated with skin cancer (e.g.
exposure to direct sunlight during the peak sun hours and use of
solaria), and which protective behaviours to perform (e.g. wearing
sunscreen that contains UVA and UVB protection and wearing
hats and other protective clothing while in the sun). Thus, in ad-
dition to providing sufficient knowledge of potential dangers to
warrant action, education programmes also offer guidance on ef-
ficacious actions to reduce the health threat if they are to success-
fully change health behaviours.
Specific components of primary education interventions (WHO
2012) may affect behaviour change by:
• reinforcing basic information about skin cancer to embed
understanding;
• emphasising adherence to UV-protective behaviours; and
• emphasising the importance of avoiding environmental
triggers.
The logic model developed by the review authors (Figure 1) shows
how educational programmes may influence skin cancer preven-
tion outcomes.
Figure 1. Logic model of how educational programmes may influence skin cancer
Why it is important to do this review
Despite strategies and efforts to prevent skin cancer, a recent re-
view highlighted the need for further research to improve skin can-
cer prevention (Lomas 2012). The incidence of both melanoma
and keratinocyte cancer has increased dramatically over previous
decades (Garbe 2009; Leiter 2012). Although melanoma is less
common than keratinocyte cancer, it is more serious than other
types of skin cancer and causes a large majority of skin cancer
deaths (AIHW 2012). Both melanoma and keratinocyte cancer
contribute to the high cancer-related health system costs (AIHW
2005; Chen 2001; Housman 2003).
There is an existing Cochrane review examining non-education
interventions (e.g. use of topical therapies, retinoids, antioxidants,
dietary modifications, and complementary therapies) for prevent-
ing keratinocyte cancer in people at high risk of developing these
cancers (Bath-Hextall 2007). Elsewhere, there are reviews of the
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use of educationprogrammes for primary-care physicians (Goulart
2011) and interventions to prevent skin cancer by reducing expo-
sure to ultraviolet radiation (Saraiya 2004), which found evidence
that education and policy interventions increase sun-protective
behaviours in primary school and in tourism or recreational set-
tings. Research findings in other settings provided insufficient ev-
idence to warrant recommending specific interventions. Despite
these limitations, educational programmes are commonly used in
an effort to prevent skin cancer.
This proposed review will attempt to evaluate the effectiveness of
educational programmes to prevent skin cancer, providing much
needed evidence to guide governmental and community organi-
sations acting in this field.
O B J E C T I V E S
To assess the effects of education programmes for skin cancer pre-
vention in the general population.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include all randomised controlled trials (RCTs) and cluster
RCTsproviding a comparisonbetween an eligible intervention and
no intervention, or between two or more eligible interventions.
Types of participants
The participants we will include are children and adults.
In this review, we will not include high-risk groups for the de-
velopment of skin cancer (e.g. transplant patients) or participants
selected for a history of skin cancer.
Types of interventions
We will include studies that compare an educational programme
with the aim of preventing skin cancer with a placebo (e.g. an edu-
cational programme about other health issues) or no intervention.
Given that this review is concerned with the effectiveness of in-
terventions for skin cancer prevention, we will exclude any pro-
grammes that do not specifically include information or educa-
tional opportunities with regard to how to prevent skin cancer
(even if we include other elements of skin cancer education). For
the purposes of this review, an educational programme will be de-
finedusing theWorldHealthOrganizationdefinition of health ed-
ucation as “consciously constructed opportunities for learning in-
volving some form of communication designed to improve health
literacy, including improving knowledge, and developing life skills
which are conducive to individual and community health” (WHO
1988, page 4).
A variety of media may deliver these interventions for a variety of
audiences, using a variety of methods, and in a variety of settings.
For example, some types of interventions may include workshops
or small groups, lectures, readings, mailed materials, role-plays,
media messages, and other educational programmes.
Wewill exclude interventions that include a policy or environmen-
tal component (unless a comparison is made of the educational
component alone), so that we can ascertain the effectiveness of the
educational programme, rather than a broader health promotion
intervention.
Types of outcome measures
Primary outcomes
The most important outcome measure would be to measure the
incidence of skin cancer following an educational programme.
Our included trials may not have a suitably long follow-up period
to analyse incidence rates, but later follow-up studies may report
these outcomes.
1. Basal cell carcinoma (BCC) incidence - ascertained by
clinical or histopathological examination, medical records, or as
reported by participants.
2. Squamous cell carcinoma (SCC) incidence - ascertained by
clinical or histopathological examination, medical records, or as
reported by participants.
3. Melanoma incidence - ascertained by clinical or
histopathological examination, medical records, or as reported by
participants.
Secondary outcomes
Secondary outcomes are predominantly proxy outcome measures
for the development of skin cancer, and sun exposure and protec-
tion knowledge, attitudes and behaviours, which are likely to be
targeted by education programmes. For each of these outcomes,
we will group available data by time point. We will categorise data
as short-term (within one month of the end of the education pro-
gramme), medium-term (within six months of the end of the ed-
ucation programme), or long-term (beyond six months after the
end of the education programme). If multiple outcomes within
one of these time intervals are reported for a secondary outcome,
we will use the outcome with the longest follow-up period within
the interval.
1. Number of naevi: Naevi are a marker of cumulative UV
exposure and subsequent melanoma risk, and may be particularly
useful for measurement of these factors among children, as
childhood is a critical time for the evolution of naevi (Harrison
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2000; LaVigne 2005) and as children are unlikely to
demonstrate skin cancers within a trial follow-up.
2. Prevalence of actinic keratoses (AKs) - ascertained by
clinical examination, medical records, or as reported by
participants; although non-malignant per se, AKs may progress
to SCCs (Cohen 2010).
3. Number of sunburn episodes or number of severe sunburn
episodes since the educational programme - questionnaire
results. Although subject to recall errors or social desirability
biases, the number of recent sunburns is commonly used as a
measure of the efficacy of skin cancer prevention interventions
(Buller 2011). Questionnaires commonly define sunburns as
referring to skin reddening or pain, lasting at least 12 hours or
one day; severe sunburns are commonly defined as sunburn with
blisters (Buller 2011).
4. Sun exposure since the educational programme - self-
reported (e.g. via a diary) or measured via dosimetry badges.
5. Usual sun protection and tanning behaviours (hat-wearing,
sunscreen application, staying in shade, umbrella use, use of
sunglasses, wearing long sleeves, and solarium use) -
observational or questionnaire results.
6. Attitudes, beliefs, and intentions regarding sun exposure
and sun protection behaviours - questionnaire results.
7. Awareness or knowledge, or knowledge recall regarding skin
cancer - questionnaire results.
8. Serum 25(OH)-vitamin D concentrations: We have
included vitamin D concentrations as a secondary (adverse)
outcome.
9. Costs associated with the intervention, including direct and
indirect costs to the intervention provider (labour and
educational materials, etc).
Search methods for identification of studies
We aim to identify all relevant RCTs regardless of language or pub-
lication status (published, unpublished, in press, or in progress).
Electronic searches
We will search the following databases to identify reports of rele-
vant RCTs and cluster RCTs:
• the Cochrane Skin Group Specialised Register;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library;
• MEDLINE via OVID (from 1946);
• EMBASE via OVID (from 1974);
• PsycINFO via OVID (from 1806);
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982);
• CINAHL via EBSCO (Cumulative Index to Nursing and
Allied Health Literature, from 1981); and
• Web of Science.
We have devised a draft search strategy for RCTs for MEDLINE
(OVID), which is displayed in Appendix 1. This search strategy
will be used as the basis for search strategies for the other databases
listed.
Trials registers
We will search the following trials registers:
• The metaRegister of Controlled Trials (www.controlled-
trials.com).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organization International Clinical
Trials Registry platform (www.who/int/trialsearch).
• The EU Clinical Trials Register (
www.clinicaltrialsregister.eu/).
Searching other resources
References from included studies
We will check the bibliographies of included studies for further
references to relevant trials.
Unpublished literature
We will search the ProQuest Dissertations and Theses
database (http://www.proquest.com/en-US/catalogs/databases/
detail/pqdt.shtml) for grey literature.
Adverse effects
We will not perform a separate search for adverse effects of the
target intervention. However, we will examine data on adverse
effects from the included studies we identify.
Data collection and analysis
We plan to include at least one ’Summary of findings’ table in
our review. In this table, we will summarise the primary outcomes
for the most important comparison. If we feel there are several
major comparisons or that our findings need to be summarised
for different populations, we will include further ’Summary of
findings’ tables.
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Selection of studies
We will download references obtained from all sources and into
a reference management software package and remove duplicates.
Two authors (DL and AD)will independently pre-screen all search
results (titles and abstracts) for possible inclusion based on specific
inclusion criteria. We will obtain the full text of selected articles
and group multiple publications about the same study together.
The same two authors will independently assess the full text of
selected articles against the inclusion criteria, with any discrep-
ancies resolved by consensus, with a third author (RC) acting as
arbiter and making the final decision for inclusion in the review if
disagreements persist.
Data extraction and management
We modified the data extraction template developed by the
Cochrane SkinGroup as necessary for this review (Table 1), andwe
will pilot the modified form with the first three eligible studies to
identify any further modifications required and amend as needed.
Two authors (DL and AD) will independently extract data using
this form. A third review author (RC) will clarify any inconsisten-
cies between authors. Two authors (DL and AD) will enter the
data into RevMan independently and clarify any inconsistencies
with a third author (LM).
Assessment of risk of bias in included studies
Two authors (DL and AD) will independently assess risk of bias
in included studies in seven domains (random allocation sequence
generation, allocation concealment, blinding of participants and
personnel, blinding of outcome assessment, incomplete outcome
data, selective outcome reporting, and other sources of bias) using
The Cochrane Collaboration’s tool for assessing risk of bias in the
Cochrane Handbook for Systematic Reviews of Interventions, Chapter
8 (Higgins 2011). We will contact study authors for additional
information about study methods as necessary to assess risk of
bias. We will complete a ’Risk of bias’ table for each eligible study,
characterising each study as at ’low’, ’unclear’, or ’high’ risk of bias
for each domain. We will categorise and report the overall risk of
bias of included studies according to the following criteria: low risk
of bias (low risk of bias for all key domains); unclear risk of bias
(unclear risk of bias for one or more key domains); and high risk
of bias (high risk of bias for one or more key domains) (Higgins
2011). A third author (RC) will resolve any disagreement related
to assessment of risk of bias.
Measures of treatment effect
We will summarise continuous outcomes using the difference of
the mean outcomes of the treatment groups with 95% confidence
intervals (CIs) or where continuous outcomes are measured using
different measures or scales, using standardised mean difference
and 95% confidence intervals. We will summarise dichotomous
outcomes using risk ratios with 95% CIs. If time-to-event data are
provided (e.g. time from randomisation to diagnosis with a skin
cancer) and if sufficient data are available, we will summarise these
data using hazard ratios or convert to dichotomous data (i.e. we
will count the number of people who were diagnosed with a skin
cancer in a particular time point). We will only dichotomise when
all participants were followed up to the particular time point. We
will determine the time point to use for dichotomisation based on
the follow-up periods of the individual studies included. If hazard
ratios cannot be obtained and dichotomisation is not possible, we
will exclude this outcome from meta-analyses, although we will
present results in narrative form.
We will analyse data using The Cochrane Collaboration’s Review
Manager 5 software.
Unit of analysis issues
This review will include studies implemented at the individual,
school, work, or community level. As such, study outcomes may
be reported at the individual or group level. We will determine
whether studies that randomise or allocate clusters have taken the
effect of clustering into account (for example, using multi-level
models, variance components analysis, or generalised estimating
equations). Where clustering has not been taken into account,
and if sufficient data are available (i.e. the number of clusters
randomised to each intervention group, outcomedata ignoring the
cluster design for the total number of individuals, and an estimate
of the intraclass correlation coefficient), we will employ statistical
methods that allow analysis at the level of the individual whilst
accounting for the clustering in the data. We will use the generic
inverse variance method with effect estimates and their standard
errors from correct analyses of cluster randomised trials. We will
identify re-analysed data as such in the review.
We may combine the results of individually randomised and (cor-
rectly analysed or re-analysed) cluster randomised trials in meta-
analyses, depending on the heterogeneity of the trials. If we per-
form such meta-analyses, we will identify cluster randomised trials
as such and conduct sensitivity analyses to investigate the robust-
ness of the conclusions.
As recommended in theCochrane Handbook for Systematic Reviews
of Interventions (section 16.5), where more than two relevant in-
tervention groups are included in the intervention, we will, if pos-
sible, combine groups to create a single pair-wise comparison.
Dealing with missing data
Analyses will follow intention-to-treat principles, where we will
analyse participants according to their allocated treatment groups
irrespective of levels of compliance.Wewill attempt to contact lead
study authors where there are missing or unclear data to obtain
additional data. Where it is not possible to obtain additional data,
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we will record this in the data extraction form and report in the
’Risk of bias’ table for the study, and we will analyse available
cases, based on the number of participants for whom outcome
data are available. We will not perform imputation from other
studies as it is assumed the data are missing at random. We may
perform sensitivity analyses to assess the sensitivity of the results
to this assumption, and we will address the potential impact of
missing data in the discussion section. If standard deviations (SD)
are missing, where appropriate, we will compute the SD from
the standard error or confidence intervals as recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (section
7.7.3).
Assessment of heterogeneity
We anticipate that the studies identified in this review will be
heterogeneous with respect to settings, participants, interventions,
and outcomes analysed. We will make the decision whether to
undertake a meta-analysis after we have extracted data. We will
assess heterogeneity by examining forest plots and quantify it using
the I² statistic for statistical heterogeneity, togetherwith the P value
from the Chi² test for statistical heterogeneity. We will consider
results heterogeneous if we obtain an I² statistic value greater than
50% and the P value from the Chi² test is less than 0.10 (Higgins
2011). In this case, we will not pool studies for meta-analysis, and
if the appropriate data are available, we will explore the potential
causes of heterogeneity by subgroup analysis.
Assessment of reporting biases
Wewill report each outcome separately. As recommended inChap-
ter 8 of the Cochrane Handbook for Systematic Reviews of Interven-
tions, if we identify sufficient studies (at least 10 for each outcome),
we will use funnel plots to plot study effect size against sample size
to assess publication bias.
Data synthesis
We will report all outcomes, whether or not statistically signifi-
cant. After we have extracted data, we will examine heterogene-
ity and decide whether to complete a meta-analysis. If the data
are sufficiently homogeneous in design, methodology, and out-
comes to conduct a meta-analysis, we will use a random-effects
model to calculate a weighted intervention effect across trials. We
have chosen a random-effects analysis as we anticipate consider-
able variation across studies, and this analysis allows more varia-
tion than only sample variation within studies. We will report the
results from the meta-analysis as pooled mean differences (con-
tinuous variables using the same scale), pooled standardised mean
differences (continuous variables using different scales), risk ra-
tios (dichotomous variables), or hazard ratios (time-to-event data)
and corresponding 95% CIs. Where sufficient data are available,
where we estimate results for individual studies with low numbers
of outcomes (< 10 in total), or where the total sample size is less
than 30 participants, we will report the proportion of outcomes
in each treatment group together with a P value from a Fisher’s
Exact test.
Subgroup analysis and investigation of heterogeneity
If there is evidence of substantial heterogeneity (I² statistic > 50%)
amongst included studies, we will explore reasons for this hetero-
geneity. We will perform subgroup analyses where sufficient data
are available, grouping the trials by the following:
• age group at start of intervention (for example, children
versus adults);
• content of intervention;
• type of intervention (channel of delivery of message, such as
written information, didactic small group sessions); and
• low- to middle-income or high-income country.
Sensitivity analysis
We will perform a sensitivity analysis for studies with low risk of
bias, as reported in the ’Risk of bias’ tables, to establish how they
impact on the results.
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A D D I T I O N A L T A B L E S
Table 1. Draft data extraction form
Ref no.: First author:
Year: Journal:
Reviewer’s name:
Eligibility of Study for Review (All must be checked for inclusion in study)
Study
design:
Randomised controlled trial or Cluster randomised trial
Partici-
pants:
Relevant according to the PICO inclusion criteria? (Children and adults, excluding high-risk groups for the development
of skin cancer or participants selected for a history of skin cancer)
Inter-
vention:
Relevant according to the PICO inclusion criteria? (Compare educational programmes with other educational pro-
grammes, placebo or no intervention; excluding interventions with policy or environmental component)
Do not proceed with data extraction if answers to any of the above questions are not checked.
If study to be included in the ’Excluded studies’ section of the review, record the reason for exclusion below
Reason for exclusion:
Setting: (where was this study conducted?)
Start and end date (including follow-up times)
Funding source (including role of funders if known)
Conflict of interest
Participants:
- population, setting
- inclusion/exclusion criteria
- demographics, comorbidities, socioeconomic status
- subgroups measured/reported
Ethics approval
Consent
Co-interventions
Were validated outcome measures used? (yes/no, for which
measures)
Group A (Intervention) Group B (Control)
Mean Age (SD) (range)
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Table 1. Draft data extraction form (Continued)
Sex (F/M)
Clusters (if applicable): no., type, no. people per cluster
Losses to follow up
Reason 1
Reason 2
Reason 3
Number lost to follow up (with %)
Final number of participants
Participants excluded from the study Number: Number:
Reason: Reason:
No exclusion reported (please circle) No exclusion reported
(please circle)
Number excluded before randomisation: Number excluded before
randomisation
Number excluded after randomisation: Number excluded after
randomisation
Not clear (please circle) Not clear (please circle)
INTERVENTIONS:
Group A (Intervention) Group B (Control)
Describe the interventions each group received
- Specify theoretical basis of intervention
- Duration, timing, delivery, providers of intervention
-Were instructions given to participants adequate?Give details
or integrity of delivery and compliance
Describe any co-interventions
TYPES OF OUTCOME MEASURES:
Outcome name: Outcome definition (scale used or how it was measured)
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Table 1. Draft data extraction form (Continued)
Primary outcome 1: Basal cell carcinoma (BCC) incidence Basal cell carcinoma (BCC) incidence ascertained by clinical or
histopathological examination, medical records or as reported by par-
ticipants
Primary outcome 2: Squamous cell carcinoma (SCC) inci-
dence
Squamous cell carcinoma (SCC) incidence - ascertained by clinical
examination or histopathological, medical records or as reported by
participants
Primary outcome 3: Melanoma incidence Melanoma incidence ascertained by clinical examination or
histopathological, medical records or as reported by participants
Secondary outcome 1: Number of naevi Number of naevi
Secondary outcome 2: Prevalence of actinic keratoses (AKs) Prevalence of actinic keratoses (AKs) ascertained by clinical examina-
tion, medical records or as reported by participants
Secondary outcome 3: Number of sunburn or severe sunburn
episodes
Number of sunburn episodes or number of severe sunburn episodes
since the educational programme - questionnaire results
Secondary outcome 4: Sun exposure Sun exposure since the educational programme - self-reported (e.g.
via a diary) or measured via dosimetry badges
Secondary outcome 5: Usual sun protection and tanning be-
haviours
Usual sun protection and tanning behaviours (hat wearing; sunscreen
application; staying in shade; umbrella use; use of sunglasses; wearing
long sleeves; solarium use) - observational or questionnaire results
Secondary outcome 6: Attitudes, beliefs and intentions regard-
ing sun exposure and sun protection behaviours
Attitudes, beliefs and intentions regarding sun exposure and sun pro-
tection behaviours - questionnaire results
Secondary outcome 7: Awareness, knowledge, or knowledge
recall regarding skin cancer
Awareness or knowledge, or knowledge recall regarding skin cancer -
questionnaire results
Secondary outcome 8: Vitamin D concentration Serum 25(OH)-vitamin D concentrations (adverse outcome)
Secondary outcome 9: Intervention costs Costs associated with the intervention, including direct and indirect
costs to the intervention provider (labour, educational materials, etc)
OUTCOMES REPORTED IN THIS PAPER RELEVANT TO REVIEW:
Outcome: Reported in this paper? (scale used or how the outcomes were
measured and timing of data collection) (please circle)
Primary outcome 1: Basal cell carcinoma (BCC) incidence YES/NO
Primary outcome 2: Squamous cell carcinoma (SCC) inci-
dence
YES/NO
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Table 1. Draft data extraction form (Continued)
Primary outcome 3: Melanoma incidence YES/NO
Secondary outcome 1: Number of naevi YES/NO
Secondary outcome 2: Prevalence of actinic keratoses (AKs) YES/NO
Secondary outcome 3: Number of sunburn or severe sunburn
episodes
YES/NO
Secondary outcome 4: Sun exposure YES/NO
Secondary outcome 5: Usual sun protection and tanning be-
haviours
YES/NO
Secondary outcome 6: Attitudes, beliefs and intentions regard-
ing sun exposure and sun protection behaviours
YES/NO
Secondary outcome 7: Awareness or knowledge, or knowledge
recall regarding skin cancer
YES/NO
Secondary outcome 8: Vitamin D concentration YES/NO
Secondary outcome 9: Intervention costs YES/NO
RESULTS:
Dichotomous (categorical) data table:
Outcome (use 1 row for each
time point)
Group A (Intervention)
Number/Total number (%)
Group B (Control)
Number/Total number (%)
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Table 1. Draft data extraction form (Continued)
Continuous data (scale) table
Outcome (use 1 row for each
time point)
Group A (Intervention)
Mean (SD)
Group B (Control)
Mean (SD)
Other information that you feel is relevant to results
Indicate below if results were estimated from graphs, etc, or calculated using a formula (this should be stated in the review
and the formula given). (In general, if results were not reported in the paper, but were obtained from another source, this should be
made clear in the review)
’Risk of bias’ assessment:
Domain Risk of bias Support for judgement
(include direct quotes
where available with ex-
planatory comments)
Support for judgement
(include direct quotes
where available with ex-
planatory comments)
Support
for judge-
ment
(include di-
rect quotes
where
available
with ex-
planatory
comments)Low High Unclear
Random sequence
generation (selection
bias)
Allocation conceal-
ment (selection bias)
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Table 1. Draft data extraction form (Continued)
Blinding of partici-
pants and personnel
(performance bias)
Outcome group: All/
(If separate judge-
ment by outcome(s)
required)
Outcome group:
Blinding of
outcome assessment
(detection bias)
Outcome group: All/
(If separate judge-
ment by outcome(s)
required)
Outcome group:
Incomplete out-
come data (attrition
bias)
Outcome group: All/
(If separate judge-
ment by outcome(s)
required)
Outcome group:
Selective outcome
reporting? (reporting
bias)
Other bias
Notes:
Questions to ask authors/responses
Date: / /2014 Reviewer Signature:
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A P P E N D I C E S
Appendix 1. MEDLINE (OVID) draft search strategy
1. exp Skin Neoplasms/
2. skin neoplas$.ti,ab.
3. skin cancer$.ti,ab.
4. exp Carcinoma, Basal Cell/
5. basal cell carcinoma$.ti,ab.
6. basal cell epithelioma$.ti,ab.
7. basalioma$.ti,ab.
8. exp Melanoma/
9. (melanoma or nonmelanoma or non-melanoma or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyte$).ti,ab.
10. nmsc.ti,ab.
11. non melanoma skin cancer$.ti,ab.
12. or/1-11
13. exp Carcinoma, Squamous Cell/
14. squamous cell carcinoma$.ti,ab.
15. 13 or 14
16. exp Skin/
17. (skin or epiderm$ or cutaneous).ti,ab.
18. 16 or 17
19. 15 and 18
20. 12 or 19
21. exp Education/
22. Health Education/
23. health promotion.ti,ab.
24. Patient Education as Topic/
25. Health Behavior/
26. consumer health information/ or health literacy/
27. workshop$.ti,ab.
28. lecture$.ti,ab.
29. leaflet$.ti,ab.
30. Teaching/
31. Role Playing/
32. (role play$ or role-play$).ti,ab.
33. group work.ti,ab.
34. newsletter$.ti,ab.
35. curriculum.ti,ab.
36. role model$.ti,ab.
37. coaching.ti,ab.
38. modelling.ti,ab.
39. video.ti,ab.
40. instruction.ti,ab.
41. Learning/
42. Counseling/
43. training.ti,ab.
44. Health Knowledge, Attitudes, Practice/
45. or/21-44
46. randomized controlled trial.pt.
47. controlled clinical trial.pt.
48. randomized.ab.
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49. placebo.ab.
50. clinical trials as topic.sh.
51. randomly.ab.
52. trial.ti.
53. 46 or 47 or 48 or 49 or 50 or 51 or 52
54. exp animals/ not humans.sh.
55. 53 not 54
56. 20 and 45 and 55
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